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Sclerosing skin diseases such as localized scleroderma
or lichen sclerosus frequently result in significant morbid-
ity that requires treatment. Until 10 years ago, no general-
ly effective treatment was available for these diseases. In
1992, extracorporeal photopheresis was suggested as
treatment for systemic sclerosis, but further studies are
required to confirm this early report [1–3]. Two years lat-
er, psoralen + UVA, in PUVA bath photochemotherapy,
was proposed as effective and safe treatment for localized
scleroderma [4]. Since then, it has been shown that all
three modes of photochemotherapy, oral PUVA, cream
PUVA and PUVA bath photochemotherapy can improve
localized scleroderma, but the PUVA bath seems to be the
most efficient mode [5–8]. In addition, phototherapy with
UVA1 irradiation may resolve established sclerosis,
whether applied as high-dose UVA1 (100–120 J/cm2) or
at doses around 30 J/cm2 [8–11]. Due to the nature of
phototherapy, placebo-controlled studies cannot be per-
formed. Meta-analysis of the various studies confirms
that sclerosis resolves either partially or completely in
about 60% of patients receiving 36 treatments of PUVA
bath therapy at slightly suberythematous doses or 36
treatments of UVA1. The mechanisms underlying the
therapeutic principle remain enigmatic. Molecular analy-
sis of resolving plaques shows a strong increase in the
expression of matrix metalloproteinase mRNA such as
collagenases and a reduction of procollagen [12–14]. Fur-
thermore, phototherapy has a strong influence on the
functioning of immune cells in the skin [15] suggesting
that the therapeutic effect relies on the modulation of col-
lagen synthesis.
Based on the success of phototherapy in the treatment
of localized scleroderma and eczema [7], several groups
analyzed the role of either UVA1 or photochemotherapy
in lichen sclerosus. The data of a manuscript reported on
pages 245–248 as well as two case reports and one more
extended description show that some patients with lichen
sclerosus may improve when receiving either cream
PUVA or UVA1 therapy [16–18]. However, the number
of patients reported until now is relatively small, and the
therapeutic modalities, including the mode of photothera-
py and the number of treatments, vary widely. Together,
the data suggest that phototherapy may be helpful in at
least some patients with lichen sclerosus. Similarly, we
found that 30 treatments of PUVA bath photochemother-
apy or of UVA1 phototherapy may help in selected
patients with extragenital lichen sclerosus, but the results
were less convincing than in the treatment of localized
scleroderma.
Importantly, while phototherapy is the only treatment
helpful in scleroderma, the situation is different in lichen
sclerosus. More than 80% improve significantly when
treated with clobetasol propionate cream, and most pa-
tients with persistent lesions of lichen sclerosus did re-
ceive inadequate treatment with topical corticosteroids
[19, 20]. Therefore, we consider PUVA bath photochemo-
therapy or medium-dose UVA1 phototherapy as first-line
therapy of localized scleroderma and topical steroids as
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first-line therapy of extragenital or genital lichen sclero-
sus. The same rules apply to the treatment of children
[21], especially as localized scleroderma may cause con-
strictions [5]. The data reported here and earlier [16–18]
suggest that selected patients with lichen sclerosus may
profit from either cream PUVA or UVA1. Detailed stud-
ies are required to characterize these patients more pre-
cisely and to define the exact role of phototherapy in the
treatment of lichen sclerosus.
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